3 Stocks That Could Trounce the Market in 2024

Three Motley Fool contributors think healthcare stocks Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals will beat the market in 2024.

Here's why: Eli Lill Three evenue growth should be even stronger than it was Eli Lilly . NYSE rt LLY is Novo Nordisk li NYSE si NVO ficant Vertex Pharmaceuticals he company VRTX ystic fibrosis drugs.

Vertex plan 2024 file for U.S. approval of non-opioid pain drug by mid-2024.

COO Stuart Arbuckl Prosper Junior Bakiny ti Eli Lilly ollar opportunity" for VX-548 in acute pain alone.

Goldman Sachs says Casgevy could Eli Lilly ak ann the past year the ballpark of $3.9 billion. The Motley Zepbound an> 2024 3 Eli Lilly's maryFeed_highLightText__NxlGi">The Motley Fool Novo Nordisk 3 Vertex Pharmaceutic this year > The Motley Fool Eli Lilly's ighLightText__NxlGi">Vertex Pharmaceuticals Prosper Junior Eli Lilly's n> Vertex Pharmaceuticals Keith Speights David Jagielski the years ahead ">February 6, 2024 Donanemab hLightText__NxlGi">9 Vertex Pharmaceuticals Eli Lilly's 0 last year ey Fool Stock Advisor two decades 1,000 COVID-19 t__NxlGi">the next few years last year aryFeed_highLightText__NxlGi">Vertexthis year class Eli Lilly Feed_highLightText__NxlGi">PEG 0.58 Novo Nordisk's ightText__NxlGi">Vertex this year s David Jagielski highLightText__NxlGi">APOL1 Novo Nordisk ighLig another strong year curr 2024 quarter 3 Wegovy ">Vertex two pan> Vertex multibill Last year r 31% high 232 billion Danish kroner n> $34.8 billion ="summaryFeed_highLightText__NxlGi">COO Stuart Arbu Ozempic pan> mid-2024 60% ed_hig a year ago __NxlGi">U.S. Goldman Sachs Wegovy ss="summary five _highLightText__NxlGi">$3 a year ago annual Novo Nordisk ummaryFeed_highLightTe Novo Holdings sgevy Catalent htText__NxlGi">2024 Casgev Wegovy n> Novo Nordisk LightText__NxlGi">Vertex Vertex Vertex P the Food and Drug Administration ss="summaryFeed_highLightText_ Wegovy ">Vertex Pharmaceuticals Keith Speights the first half of this year NxlGi">first Novo Nordisk's 35